A paper describing the potentials of Nichi Glucan as a vaccine adjuvant to COVID-19 has been published in Human Vaccines and Immunotherapeutics, a journal sponsored by the International Society of Vaccines.
Clinical studies in Covid-19 and its variants to tackle the pandemic, recommended.
To read the press release in Business Wire, click here.
Please visit nichiglucan.com for more information about Nichi Glucan.
At International Conference in Yokohama, Japan 17 Aug 2024 Nichi BRITE Beta glucan administration resulted in
At the MENA Conference on Rare DiData presented in IFPA 7th World Psoriasis conference, in Stockholm, Sweden 0
Cliny PEG Gastrostomy kits of Create Medic launched in India by Medinippon, GNCorp sister company 11Aug2023 Ja
Japanese scientists, research collaborators to Nichi-in Centre for Regenerative Medicine (NCRM) have reported an increased yield of Beta 1,3-1,6 glucans in the produc
Clinical study results of Neu REFIX B-glucans & research updates by Dr. K. Raghavan 06 Oct 2024 Dr. Raghav
Neu REFIX pre-clinical studies in mdx mice @ AOMC-JMS 2024 05 Oct 2024 Disease modifying approach in managing
At the MENA Conference on Rare DiData presented in IFPA 7th World Psoriasis conference, in Stockholm, Sweden 0
“neu REFIX ” potentials in Duchenne Muscular Dystrophy will be presented at Congress held in UAE
